New drug aims to stop hip bone death from steroids

NCT ID NCT07471880

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called RAB001 in people with early-stage hip bone damage caused by long-term steroid use. About 160 participants will receive either a low, medium, or high dose of RAB001, or a standard bone drug (alendronate). The goal is to see if RAB001 can reduce the size of the damaged bone area and improve hip function over 48 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
RAB001 (a drug that targets bone repair) and alendronate (Fosamax, a standard bone drug)
What this could lead to
If it works, this could point toward a treatment that slows or reverses bone damage in the hip, potentially delaying or avoiding the need for joint replacement.
What could go wrong
This is an early Phase 2 trial with only 160 people, so results may not apply to everyone. The drug may not work better than the standard treatment, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEONECROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ZhongShan LaiBo RuiChen BioMedicine Co.,Ltd.

    Zhongshan, Guangdong, 528400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.